Introduction
============

Renal cell cancer/carcinoma (RCC) is considered to be one of the most treatment-resistant cancers and is the tenth cancer-related cause of death in USA, with an estimated 39,140 new cases and 8,900 deaths in 2014.[@b1-ott-8-1581] In People's Republic of China, the incidence of RCC is relatively low and accounts for 2% of adults' malignant tumors. In nearly 20 years, the morbidity of RCC increases at an average of 6.5% per year. Its cancer-related mortality exceeds the bladder cancer and ranks the first in the genitourinary cancer.[@b2-ott-8-1581] Due to the social, economic, and environmental factors, about half of the Chinese patients with RCC have been found in advanced stage at diagnosis and the curative effect is not satisfactory with traditional treatment strategies. In recent years, targeted therapies have dramatically improved prognosis of patients with metastatic renal cell cancer (mRCC). Sorafenib (Nexavar, Bayer AG, Leverkusen, Germany), a representative multikinase inhibitor of tumor-cell proliferation and angiogenesis, is a kind of novel multitargeting micromolecule compound aiming at vascular endothelial growth factor (VEGF). It is the first molecular-targeting agent approved by the FDA for patients with mRCC. Some international collaborative Phase III trials demonstrated that sorafenib could obviously improve progression-free survival (PFS) with tolerable toxicities in patients with mRCC.[@b3-ott-8-1581]--[@b5-ott-8-1581] Until now, it still lacks the long-term follow-up data on overall survival (OS) and PFS from Asian patients. The objective of this study was to observe long-term efficacy of sorafenib and make an effort to explore the impact factors on prognosis in Chinese patients with mRCC.

Patients and methods
====================

Clinical data
-------------

In this retrospective study, 406 consecutive patients were diagnosed as mRCC histopathologically between October 2007 and October 2010 from six comprehensive cancer centers in Northeast China. The primary metastatic sites included viscera (liver and lungs), bones, and lymph nodes. First, we excluded 266 patients who accepted nephrectomy or immunotherapy alone without sorafenib. Second, we excluded nine patients who were lack of adequate follow-up data. The Eastern Cooperative Oncology Group performance status (ECOG PS) of 131 patients enrolled in this study was 0--2 ([Figure 1](#f1-ott-8-1581){ref-type="fig"}). The cutoff date for follow-up and data statistics was October 2013. All patients received 400 mg of sorafenib orally twice daily on a continuous basis until progression of disease or occurrence of intolerable toxicities. OS (definition as the time from initiation of sorafenib therapy to death) and PFS (definition as the time from initiation of sorafenib therapy to the first documentation of disease progression or to death from any cause, whichever occurred first) were appointed as main outcome measures. In addition, the influence of sex, ECOG PS, primary metastatic sites, and previous therapy on survival in patients were observed. The relationship between clinical variables and prognosis of patients was also evaluated.

Statistical analyses
--------------------

Clinical data were analyzed using the SPSS statistical software (version 17.0, SPSS Inc., Chicago, IL, USA). OS and PFS curves were drawn using the Kaplan--Meier method. Clinical variables were included on univariate and multivariate analysis to evaluate associations with OS and PFS by the log-rank test and Cox proportional hazard models, *P*\<0.05 was considered as statistically significant.

Results
=======

A total of 131 patients were available for survival analysis, including 96 males and 35 females. The median age was 60 years (33--79 years). By October 2013, the median follow-up periods were 16.9 months (0.6--48.5 months). The baseline characteristics of patients are shown in [Table 1](#t1-ott-8-1581){ref-type="table"}. According to the results of survival analysis, the median OS was 16.1 months and the median PFS was 10.5 months ([Figure 2](#f2-ott-8-1581){ref-type="fig"}). OS of patients with ECOG PS 0/1 was 24.6 months and 19.1 months, respectively, which was significantly better than 7.1 months of those cases with PS 2. Compared with metastatic lesions such as viscera, lymph nodes, and bones, patients with multiple organs metastasis had the worst prognosis. According to the conditions of previous therapy, patients who undergo nephrectomy + immunotherapy or immunotherapy alone had a longer lifetime than those who only undergo surgery or untreated. Univariate analysis showed that PFS for patients with ECOG PS 0/1 was better than those cases with PS 2. In addition, patients who undergo nephrectomy + immunotherapy or immunotherapy alone had a longer PFS than those cases who only undergo surgery or untreated ([Table 2](#t2-ott-8-1581){ref-type="table"}). ECOG PS, metastatic lesions, and previous therapy were predictive factors for OS in Cox proportional hazard models ([Figure 3](#f3-ott-8-1581){ref-type="fig"}). ECOG PS and previous therapy were predictive factors for PFS in Cox proportional hazard models ([Figure 4](#f4-ott-8-1581){ref-type="fig"}). In the subgroup analysis for 78 patients with visceral metastasis, the prognosis of patients with lung metastasis alone was better than those cases with liver metastasis alone or multiple organs metastasis ([Figure 5](#f5-ott-8-1581){ref-type="fig"}). Subsequently, the multivariate analysis suggested that ECOG PS (*P*=0.004), metastatic lesions (*P*=0.003), and previous therapy (*P*=0.019) were the independent prognostic factors for OS, and ECOG PS (*P*=0.000) and previous therapy (*P*=0.003) as the independent prognostic factors for PFS ([Tables 3](#t3-ott-8-1581){ref-type="table"} and [4](#t4-ott-8-1581){ref-type="table"}).

Discussion
==========

RCC is one of the most common malignant tumors in Caucasian and one-third of cases with localized RCC eventually develop metastatic disease despite surgical resection of the primary tumor.[@b6-ott-8-1581],[@b7-ott-8-1581] In People's Republic of China, 20%--30% of patients with RCC have metastases at diagnosis and 20%--40% of postnephrectomy patients will subsequently develop metastases.[@b8-ott-8-1581],[@b9-ott-8-1581] Metastasis is the leading cause of death in Chinese patients with RCC, and previously we lack effective treatment strategy for mRCC.

During the past few years, strategies targeted at VEGF, platelet-derived growth factor, and the mammalian target of rapamycin pathway dominate in RCC treatment. As a representative drug, sorafenib brings great benefit to Asian patients.[@b10-ott-8-1581] It is a novel signal transduction inhibitor that can inhibit RAF-1 and B-RAF serine/threonine kinase activities as well as VEGF-2, VEGF-3, platelet-derived growth factor-β, KIT, and FLT-3 tyrosine kinases.[@b11-ott-8-1581] It also has double-antitumor activity that directly inhibits tumor-cell proliferation by blocking the RAF/MEK/ERK pathways or inhibits neovascularization by cutting off nutritional supply to tumor cells.[@b12-ott-8-1581]--[@b14-ott-8-1581] However, it still lacks data about sorafenib from Asian patients with mRCC in a large sampling and long-term follow-up profile.

This study was the first major clinical retrospective investigation for mRCC in Northeast China. After more than 3 years follow-up for all cases, we found that the median OS and PFS were 16.1 months and 10.5 months, respectively. The median OS in this study was similar to the data from some European and American research, but there were differences in median PFS.[@b15-ott-8-1581]--[@b17-ott-8-1581] In the global Phase III study TARGET, the final OS and PFS of Caucasian patients receiving sorafenib were 17.8 months and 5.5 months, respectively.[@b5-ott-8-1581] Compared with the TARGET study, the median PFS of our study was much longer (10.5 months vs 5.5 months). The results of our study were consistent with reported data from a small sampling of Chinese patients, which were little different from other Asian non-Chinese data.[@b9-ott-8-1581],[@b18-ott-8-1581] In a Japanese study, they found that the median PFS was 7.4 months, the median OS was 25.3 months, and these results were also longer than that in the TARGET study.[@b19-ott-8-1581] Some results from another Japanese study showed that the median PFS was 9.0 months and sorafenib was effective in Japanese patients with advanced renal cell cancer in general clinical practice.[@b20-ott-8-1581] In the study of Korean patients, OS and PFS in subgroup of patients receiving sorafenib were 25.7 months and 8.6 months, respectively.[@b21-ott-8-1581] Compared with Asian non-Chinese data, we found that OS in our study was worse. The reason for this phenomenon was not clear, but it might be related to some patients who occurred to progression of disease in the early stage of sorafenib therapy. However, from the above data, Asian patients may acquire more benefit from sorafenib treatment.

At the same time, we surveyed some clinical factors that might affect the prognosis of Chinese patients with mRCC. Previous studies showed that tumor burden should be an independent prognostic factor in mRCC and c-KIT might be a potential predictive factor for the efficacy of sorafenib in mRCC with sarcomatoid feature.[@b22-ott-8-1581],[@b23-ott-8-1581] In this study, we discussed the relationship between clinical factors and prognosis. We used some statistical methods to certify that ECOG PS, metastatic lesions, and previous therapy were the independent prognostic factors for OS, and ECOG PS and previous therapy as the independent prognostic factors for PFS. Furthermore, in a retrospective study, authors found that metastatic sites were associated with PFS and OS in patients with RCC treated with targeted therapies and patients with multi-metastatic sites had shorter PFS and OS.[@b24-ott-8-1581] The subgroup analysis showed that patients with lung metastases were more sensitive to sorafenib than those with other organ metastases, which was similar to Kondo's study.[@b25-ott-8-1581] In addition, there were some limitations in our study. Retrospective data were collected from local area of the Northeast China and patient sampling was not large enough to revise the treatment guideline for mRCC. Due to a larger proportion of the enrolled patients with poor PS, the OS data were lower than that of the Asian population.

Taken together, according to the present data from European/American/Asian patients with mRCC, Asian patients may be more benefit from sorafenib treatment. This long-term follow-up study also demonstrated that Chinese patients with lung metastases were more sensitive to sorafenib than those with other organ metastases. ECOG PS, metastatic lesions, and previous therapy may be important parameters for OS and PFS prediction. Further researches on selecting the candidate patients with mRCC for sorafenib treatment should be done to confirm these findings.
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![Patient disposition.\
**Note:** This figure showed the screening process of patients.\
**Abbreviation:** mRCC, metastatic renal cell cancer.](ott-8-1581Fig1){#f1-ott-8-1581}

![Survival curve for patients with mRCC.\
**Notes:** (**A**) OS curve for all patients and the median OS was 16.1 months. (**B**) PFS curve for all patients and the median PFS was 10.5 months.\
**Abbreviations:** mRCC, metastatic renal cell cancer; OS, overall survival; PFS, progression-free survival.](ott-8-1581Fig2){#f2-ott-8-1581}

###### 

Relationship between clinical variables and OS.

**Notes:** (**A**) There was no significant difference between male group and female group for OS in patients with mRCC (*P*\>0.05). (**B**) Both groups with age \<65 years and age ≥65 years had no difference in OS (*P*\>0.05). (**C**) OS for patients with ECOG PS 0/1 was significantly better than those cases with PS 2 (24.6 months vs 7.1 months, *P*\<0.05; 19.1 months vs 7.1 months, *P*\<0.05). (**D**) Compared with other metastatic lesions such as viscera, lymph nodes, and bones, patients with multiple organs metastasis had the worst prognosis (20.4 months vs 7.7 months, *P*\<0.05; 16.0 months vs 7.7 months, *P*\<0.05; 20.7 months vs 7.7 months, *P*\<0.05). (**E**) According to the conditions of previous therapy, patients who undergo nephrectomy + immunotherapy or immunotherapy alone had a longer lifetime than those cases who only undergo surgery or untreated (22.6 months vs 6.2 months, *P*\<0.05; 22.6 months vs 5.2 months, *P*\<0.05; 19.1 months vs 6.2 months, *P*\<0.05; 19.1 months vs 5.2 months, *P*\<0.05).

**Abbreviations:** ECOG PS, Eastern Cooperative Oncology Group performance status; mRCC, metastatic renal cell cancer; OS, overall survival.
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###### 

Relationship between clinical variables and PFS.

**Notes:** (**A**) There was no significant difference between male group and female group for PFS in patients with mRCC (*P*\>0.05). (**B**) Both groups with age \<65 years and age ≥65 years had no difference in PFS (*P*\>0.05). (**C**) PFS for patients with ECOG PS 0/1 was better than those cases with PS 2 (16.1 months vs 2.9 months, *P*\<0.05; 12.3 months vs 2.9 months, *P*\<0.05). (**D**) Metastatic sites had no obvious correlation with PFS in patients with mRCC (*P*\>0.05). (**E**) Patients who undergo nephrectomy + immunotherapy or immunotherapy alone had a longer lifetime than those cases who only undergo surgery or untreated (12.4 months vs 5.3 months, *P*\<0.05; 12.4 months vs 3.1 months, *P*\<0.05; 12.3 months vs 5.3 months, *P*\<0.05; 12.3 months vs 3.1 months, *P*\<0.05).

**Abbreviations:** ECOG PS, Eastern Cooperative Oncology Group performance status; mRCC, metastatic renal cell cancer; PFS, progression-free survival.
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![Relationship between metastatic sites and OS or PFS in the subgroup of patients with visceral metastasis.\
**Notes:** (**A**) Patients with lung metastasis alone had better OS than those cases with liver metastasis alone or multiple organs metastasis (25.9 months vs 14.9 months, *P*\<0.05; 25.9 months vs 5.4 months, *P*\<0.05). (**B**) Patients with lung metastasis alone had better PFS than those cases with liver metastasis alone or multiple organs metastasis (13.1 months vs 9.3 months, *P*\<0.05; 13.1 months vs 4.4 months, *P*\<0.05).\
**Abbreviations:** OS, overall survival; PFS, progression-free survival.](ott-8-1581Fig5){#f5-ott-8-1581}

###### 

Baseline characteristics

  Characteristic              Patients, n (%)
  --------------------------- -----------------
  Sex                         
   Male                       96 (73.3)
   Female                     35 (26.7)
  Age, years                  
   \<65                       87 (66.4)
   ≥65                        44 (33.6)
  Metastatic sites            
   Lung                       99 (75.6)
   Liver                      55 (42.0)
   Bone                       41 (31.3)
   Lymph nodes                17 (13.0)
  Number of metastatic foci   
   1                          75 (57.3)
   2                          36 (27.5)
   ≥3                         20 (15.2)
  ECOG PS                     
   0                          38 (29.0)
   1                          49 (37.4)
   2                          44 (33.6)
  Prior nephrectomy           
   Yes                        95 (72.5)
   No                         36 (27.5)
  Prior immunotherapy         
   IL-2 + IFN                 46 (35.1)
   IL-2 alone                 18 (13.7)
   IFN alone                  23 (17.6)
   None                       44 (33.6)

**Abbreviations:** ECOG PS, Eastern Cooperative Oncology Group performance status; IFN, interferon; IL, interleukin.

###### 

The univariate analysis to evaluate the relationship between clinical variables and OS/PFS

  Clinical variables                                    N    Median OS (months)   95% CI           Log rank (*P*-value)                               Median PFS (months)   95% CI           Log rank (*P*-value)
  ----------------------------------------------------- ---- -------------------- ---------------- -------------------------------------------------- --------------------- ---------------- --------------------------------------------------
  Sex                                                                                                                                                                                        
   Male                                                 96   15.7                 13.396--18.004   0.243                                              9.3                   7.380--11.220    0.328
   Female                                               35   21.9                 14.598--29.202                                                      12.9                  8.940--16.860    
  Age                                                                                                                                                                                        
   \<65                                                 87   16.2                 14.006--18.394   0.128                                              10.3                  8.371--12.229    0.902
   ≥65                                                  44   17.1                 5.120--29.080                                                       10.7                  5.175--16.225    
  ECOG PS                                                                                                                                                                                    
   0                                                    38   24.6                 21.428--27.772   0.000[\*](#tfn2-ott-8-1581){ref-type="table-fn"}   16.1                  14.650--17.550   0.000[\*](#tfn2-ott-8-1581){ref-type="table-fn"}
   1                                                    49   19.1                 16.219--21.981                                                      12.3                  9.843--14.757    
   2                                                    44   7.1                  6.017--8.813                                                        2.9                   1.971--3.829     
  Metastatic sites                                                                                                                                                                           
   Multiple organs                                      39   7.7                  3.907--11.493    0.004[\*](#tfn2-ott-8-1581){ref-type="table-fn"}   2.9                   2.043--3.757     0.083
   Viscera[\#](#tfn3-ott-8-1581){ref-type="table-fn"}   78   20.4                 13.800--27.000                                                      12.3                  10.955--13.645   
   Lymph nodes                                          7    16                   14.460--17.540                                                      8.8                   7.260--10.340    
   Bones                                                7    20.7                 16.594--24.806                                                      15.6                  9.441--21.759    
  Previous therapy                                                                                                                                                                           
   Nephrectomy + immunotherapy                          70   22.6                 16.769--28.431   0.004[\*](#tfn2-ott-8-1581){ref-type="table-fn"}   12.4                  9.530--15.270    0.001[\*](#tfn2-ott-8-1581){ref-type="table-fn"}
   Immunotherapy alone                                  25   19.1                 11.705--26.495                                                      12.3                  9.208--15.392    
   Nephrectomy alone                                    17   6.2                  0.000--16.319                                                       5.3                   1.220--9.380     
   None                                                 19   5.2                  1.503--8.897                                                        3.1                   2.397--3.803     

**Notes:**

*P*\<0.05 was considered as statistically significant.

Viscera only consider the lungs and liver, except for other organs.

**Abbreviations:** CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; OS, overall survival; PFS, progression-free survival.

###### 

Multivariate analysis for OS

  Clinical variables   Odds ratio   95% CI         *P*-value
  -------------------- ------------ -------------- -----------
  ECOG PS              1.423        1.120--1.808   0.004
  Metastatic sites     0.816        0.713--0.933   0.003
  Previous therapy     0.820        0.694--0.968   0.019

**Abbreviations:** CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; OS, overall survival.

###### 

Multivariate analysis for PFS

  Clinical variables   Odds ratio   95% CI         *P*-value
  -------------------- ------------ -------------- -----------
  ECOG PS              1.561        1.233--1.977   0.000
  Previous therapy     0.775        0.654--0.918   0.003

**Abbreviations:** CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; PFS, progression-free survival.
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